The goal of this study was to assess the differences between an ex ante and an ex post cost-effectiveness analysis of Dabigatran etexilate vs VKAs for the prevention of thromboembolic events in non-valvular atrial fibrillation patients and to draw lessons
DE POUVOURVILLE, G., BLIN, P. and KARAM, P. (2020). The Contribution of Real-World Evidence to Cost-Effectiveness Analysis: Case Study of Dabigatran Etexilate in France. European Journal of Health Economics, 21, pp. 235-249.